P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE. (23rd June 2022) - Wei, A. H.; Döhner, H.; Sayar, H.; Ravandi, F.; Montesinos, P.; Dombret, H.; Selleslag, D.; Porkka, K.; Jang, J.-H.; Skikne, B.; Beach, C.; Prebet, T.; et al.